California State Teachers Retirement System Decreases Stock Holdings in Illumina, Inc. $ILMN

Posted by Geri Gentry on Aug 1st, 2026

California State Teachers Retirement System lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 2.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 236,566 shares of the life sciences company’s stock after selling 4,794 shares during the quarter. California State Teachers Retirement System’s holdings in Illumina were worth $29,159,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital World Investors increased its holdings in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after buying an additional 124,323 shares during the last quarter. State Street Corp raised its position in shares of Illumina by 3.2% during the 4th quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after buying an additional 190,324 shares in the last quarter. WCM Investment Management LLC raised its position in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Illumina by 30.3% in the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Illumina by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after acquiring an additional 130,139 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

ILMN stock opened at $205.10 on Friday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $205.93. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The company has a 50-day moving average price of $176.70 and a 200 day moving average price of $147.24. The stock has a market cap of $31.03 billion, a PE ratio of 38.26, a P/E/G ratio of 3.03 and a beta of 1.47.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 30.54%. The firm’s revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.22 earnings per share for the current year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Insider Activity

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Royal Bank Of Canada boosted their price objective on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research note on Friday. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a report on Friday. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Piper Sandler increased their price target on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 1st. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $175.47.

Check Out Our Latest Analysis on ILMN

Illumina Profile

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.